For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $0.34 in the prior trading day, IGC Pharma Inc (AMEX: IGC) closed at $0.33, down -2.23%. In other words, the price has decreased by -$2.23 from its previous closing price. On the day, 2.32 million shares were traded. IGC stock price reached its highest trading level at $0.36 during the session, while it also had its lowest trading level at $0.3278.
Ratios:
Our goal is to gain a better understanding of IGC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.32. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGC now has a Market Capitalization of 30507218 and an Enterprise Value of 29523218. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.48 while its Price-to-Book (P/B) ratio in mrq is 3.73. Its current Enterprise Value per Revenue stands at 26.694 whereas that against EBITDA is -3.924.
Stock Price History:
The Beta on a monthly basis for IGC is 0.31, which has changed by -0.08108109 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, IGC has reached a high of $0.50, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is -9.09%, while the 200-Day Moving Average is calculated to be -4.78%.
Shares Statistics:
The stock has traded on average 733.81K shares per day over the past 3-months and 805870 shares per day over the last 10 days, according to various share statistics. A total of 91.96M shares are outstanding, with a floating share count of 71.51M. Insiders hold about 23.00% of the company’s shares, while institutions hold 5.86% stake in the company. Shares short for IGC as of 1764288000 were 292751 with a Short Ratio of 0.40, compared to 1761868800 on 284005. Therefore, it implies a Short% of Shares Outstanding of 292751 and a Short% of Float of 0.42.
Earnings Estimates
. The current market rating for IGC Pharma Inc (IGC) reflects the collective analysis of 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.08 and -$0.08 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.09, with 2.0 analysts recommending between -$0.09 and -$0.09.
Revenue Estimates
1 analysts predict $193k in revenue for. The current quarter. It ranges from a high estimate of $193k to a low estimate of $193k. As of. The current estimate, IGC Pharma Inc’s year-ago sales were $257kFor the next quarter, 1 analysts are estimating revenue of $198k. There is a high estimate of $198k for the next quarter, whereas the lowest estimate is $198k.
A total of 1 analysts have provided revenue estimates for IGC’s current fiscal year. The highest revenue estimate was $910k, while the lowest revenue estimate was $910k, resulting in an average revenue estimate of $910k. In the same quarter a year ago, actual revenue was $1.27MBased on 2 analysts’ estimates, the company’s revenue will be $1.25M in the next fiscal year. The high estimate is $1.5M and the low estimate is $1M.
